Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Current Deferred Revenue (2019 - 2025)

Apyx Medical filings provide 7 years of Current Deferred Revenue readings, the most recent being $1.7 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 15.0% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 million, a 15.0% decrease, with the full-year FY2025 number at $1.7 million, down 15.0% from a year prior.
  • Current Deferred Revenue hit $1.7 million in Q4 2025 for Apyx Medical, down from $2.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.3 million in Q4 2022 to a low of $1.7 million in Q4 2023.
  • Median Current Deferred Revenue over the past 5 years was $1.9 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 216.67% in 2021 and later dropped 26.09% in 2023.
  • Apyx Medical's Current Deferred Revenue stood at $1.9 million in 2021, then rose by 21.05% to $2.3 million in 2022, then fell by 26.09% to $1.7 million in 2023, then grew by 17.65% to $2.0 million in 2024, then decreased by 15.0% to $1.7 million in 2025.
  • The last three reported values for Current Deferred Revenue were $1.7 million (Q4 2025), $2.0 million (Q4 2024), and $1.7 million (Q4 2023) per Business Quant data.